y 27632 has been researched along with candesartan in 2 studies
| Studies (y 27632) | Trials (y 27632) | Recent Studies (post-2010) (y 27632) | Studies (candesartan) | Trials (candesartan) | Recent Studies (post-2010) (candesartan) |
|---|---|---|---|---|---|
| 1,924 | 3 | 891 | 1,929 | 412 | 589 |
| Protein | Taxonomy | y 27632 (IC50) | candesartan (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.2769 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 5.9472 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.0652 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 9 | |
| Adenosine receptor A3 | Homo sapiens (human) | 1.2199 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.843 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.0652 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.0594 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0405 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, T; Kobayashi, N; Kobayashi, T; Matsuoka, H; Mita, S; Nakano, S; Tsubokou, Y | 1 |
| Dominguez-Meijide, A; Guerra, MJ; Labandeira-Garcia, JL; Lanciego, JL; Rodriguez-Perez, AI | 1 |
2 other study(ies) available for y 27632 and candesartan
| Article | Year |
|---|---|
Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats.
Topics: Amides; Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; Hemodynamics; Hypertension; Intracellular Signaling Peptides and Proteins; Male; Mitogen-Activated Protein Kinases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Organ Size; Plasminogen Activator Inhibitor 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Inbred WKY; rho-Associated Kinases; rhoA GTP-Binding Protein; Ribosomal Protein S6 Kinases; RNA, Messenger; Tetrazoles; Ventricular Remodeling | 2002 |
Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; MPTP Poisoning; Neuroprotective Agents; Ovariectomy; Pyridines; Receptor, Angiotensin, Type 1; rho-Associated Kinases; Tetrazoles; Tyrosine 3-Monooxygenase | 2013 |